ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.
- Authors:
- EM Swisher, IA McNeish, RL Coleman, J Brenton, SH Kaufmann, AR Allen, M Raponl, H Giordano, L Maloney, J Isaacson, JA Ladermann
- Journal:
- Journal of Clinical Oncology
- Citation info:
- 32(15_suppl):tps5619-tps5619
- Publication date:
- 20th May 2014
- Full text
- DOI